Sign In
Buy CELZ
$2.20
-0.0300 (-1.35%)
At Close: Jun 03, 2026
Ultrasome™ Demonstrates Strong Clinical Signal While Leveraging GMP-Produced CELZ-201 (Olastrocel) to Target Large, Underserved Osteoarthritis Market
Data Show Strong Functional and Pain Improvements Supported by Excellent Safety Profile Data Show Strong Functional and Pain Improvements Supported by Excellent Safety Profile
Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative
09:15am, Tuesday, 06'th Jan 2026
PHOENIX, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company advancing reg
Completion of Enrollment Positions CELZ for Near-Term Data Catalysts and Accelerates Path Toward Commercialization of a Transformative, Non-Opioid Therapy for Chronic Lower Back Pain Completion of Enr
Global assignment of this unique name enhances international clarity, strengthens regulatory positioning, and supports olastrocel's advancement across large unmet-need global markets Global assignment
Bears are Losing Control Over Creative Medical Technology Holdings, Inc. (CELZ), Here's Why It's a 'Buy' Now
10:55am, Wednesday, 05'th Nov 2025
Creative Medical Technology Holdings, Inc. (CELZ) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings
Creative Medical Technology Holdings, Inc. Ignites Next-Gen Regenerative BioDefense Initiative for U.S. Veterans Exposed to Burn Pits
09:15am, Thursday, 30'th Oct 2025
Selects Greenstone Biosciences to Accelerate AI-Driven iPSC Precision Medicine Platform Selects Greenstone Biosciences to Accelerate AI-Driven iPSC Precision Medicine Platform
Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.2 Million Gross Proceeds
09:00am, Wednesday, 29'th Oct 2025
PHOENIX, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc., (Nasdaq: CELZ) (the “Company”), a clinical-stage biotechnology company pioneering regenerative immunotherapy,
Creative Medical Technology Holdings Issues Letter to Shareholders
08:15am, Monday, 27'th Oct 2025
Ongoing Phase II Clinical Trials, Recently Issued Patents, and AI Integration Initiatives Set the Stage for Continuing Progress in 2026 Ongoing Phase II Clinical Trials, Recently Issued Patents, and
Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs
09:15am, Tuesday, 07'th Oct 2025
Recent Issuance of U.S. Patents Covering ImmCelz™ — Supercharged Regulatory T Cell Programs in Heart Failure and Type 1 Diabetes Reinforce Creative Medical's Similar Research Focus Recent Issuance
New Strong Sell Stocks for July 31st
06:46am, Thursday, 31'st Jul 2025
CELZ, GRFS and WHR have been added to the Zacks Rank #5 (Strong Sell) List on July 31, 2025.
PHOENIX, July 17, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company specializing
PHOENIX, July 11, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company specializing
Creative Medical Technology Holdings, Inc. (CELZ) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Tuesday, 25'th Mar 2025
Creative Medical Technology Holdings, Inc. (CELZ) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in t
Is Creative Medical Technology Holdings, Inc. (CELZ) Stock Outpacing Its Medical Peers This Year?
10:40am, Tuesday, 25'th Mar 2025
Here is how Creative Medical Technology Holdings, Inc. (CELZ) and 89BIO (ETNB) have performed compared to their sector so far this year.
